ALFA Finder India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold Telegram alerts alfafinder.com →
Saturday, 7 November 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Product Launch

AstraZeneca Pharma India Product Launch

AstraZeneca Pharma India will launch Datverzo, Datopotamab Deruxtecan, in India in November 2026. The drug holds DCGI import and market permission for HR-positive, HER2-negative breast cancer.

Source

BSE filing, NSE: ASTRAZEN. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

AstraZeneca Pharma India Ltd: key numbers

Share price
₹6,373.50
Market cap
₹15,934 Cr
Revenue (annual)
₹2,276 Cr
Net profit (annual)
₹187.5 Cr
P/E (TTM)
89.7×Sector 43.0×
Promoter holding
75.00%+0.00% QoQ
FII holding
2.64%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from AstraZeneca Pharma India Ltd

All →

Other product launch announcements

All →